Scholarlink

Background <p>Scleroderma is characterized by fibrosis of the skin and internal organs, vascular abnormalities, and immune dysregulation. Fat grafting has emerged as a promising therapeutic approach for improving soft tissue deficits and alleviating fibrosis in scleroderma patients. However, low fat graft survival and unresolved fibrosis in fibrotic tissues limit its efficacy. This study aims to evaluate the efficacy of Concentrated Micronized Fat (CMF), a mechanically processed fat product enriched with stromal vascular fraction (SVF) cells and intact adipocytes, in mitigating bleomycin-induced skin fibrosis and enhancing fat graft survival.</p> Method <p>CMF was prepared using a mechanical micronization and filtration–adsorption method to enrich stromal vascular fraction cells while retaining intact adipocytes. <i>In vitro</i> experiments assessed the effects of CMF on fibroblast proliferation and migration. A murine model of bleomycin (BLM)-induced skin fibrosis was established, and the therapeutic effects of CMF and Coleman fat were compared through <i>in vivo</i> transplantation.</p> Result <p><i>In vitro</i> experiments showed that CMF significantly inhibited fibroblast proliferation and migration. <i>In vivo</i>, CMF transplantation effectively mitigated bleomycin-induced dermal thickening and collagen deposition while promoting adipocyte survival.</p> Conclusion <p>CMF effectively alleviates skin fibrosis. It improves fat graft retention under fibrotic conditions. These results suggest that CMF is a promising therapeutic approach for treating scleroderma-related fibrosis.</p> No Level Assigned <p>This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors <a href="http://www.springer.com/00266">www.springer.com/00266</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Concentrated Micronized Fat Ameliorates Skin Fibrosis in Bleomycin‐Induced Murine Model and Enhances Fat Graft Survival

  • 期刊论文

  • 发表日期：

    2025年10月8日

查看全文
  • Xuan Ma,
  • Miao Dong,
  • Ningbei Yin,
  • Facheng Li

摘要

Background

Scleroderma is characterized by fibrosis of the skin and internal organs, vascular abnormalities, and immune dysregulation. Fat grafting has emerged as a promising therapeutic approach for improving soft tissue deficits and alleviating fibrosis in scleroderma patients. However, low fat graft survival and unresolved fibrosis in fibrotic tissues limit its efficacy. This study aims to evaluate the efficacy of Concentrated Micronized Fat (CMF), a mechanically processed fat product enriched with stromal vascular fraction (SVF) cells and intact adipocytes, in mitigating bleomycin-induced skin fibrosis and enhancing fat graft survival.

Method

CMF was prepared using a mechanical micronization and filtration–adsorption method to enrich stromal vascular fraction cells while retaining intact adipocytes. In vitro experiments assessed the effects of CMF on fibroblast proliferation and migration. A murine model of bleomycin (BLM)-induced skin fibrosis was established, and the therapeutic effects of CMF and Coleman fat were compared through in vivo transplantation.

Result

In vitro experiments showed that CMF significantly inhibited fibroblast proliferation and migration. In vivo, CMF transplantation effectively mitigated bleomycin-induced dermal thickening and collagen deposition while promoting adipocyte survival.

Conclusion

CMF effectively alleviates skin fibrosis. It improves fat graft retention under fibrotic conditions. These results suggest that CMF is a promising therapeutic approach for treating scleroderma-related fibrosis.

No Level Assigned

This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.